Jazz Pharmaceuticals JAZZ Non-deductible contingent consideration payments
Non-deductible contingent consideration payments at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:EffectiveIncomeTaxRateReconciliationNonDeductibleContingentConsiderationPaymentsPercent.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's non-deductible contingent consideration payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's non-deductible contingent consideration payments?
- Jazz Pharmaceuticals (JAZZ) reported non-deductible contingent consideration payments of -1.2% in Q4 2025.
- What does non-deductible contingent consideration payments mean?
- The tax cost associated with acquisition payments that cannot be deducted from taxable income.
- How do you interpret non-deductible contingent consideration payments?
- An increase indicates higher non-deductible acquisition costs, which negatively impacts the effective tax rate.
- How does non-deductible contingent consideration payments compare across companies?
- Common in M&A-heavy biopharma firms; peers often disclose this as a permanent difference in tax reconciliations.